GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » EBITDA Margin %

MBCOF (Marvel Biosciences) EBITDA Margin % : 0.00% (As of Jul. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Marvel Biosciences's EBITDA for the three months ended in Jul. 2024 was $0.00 Mil. Marvel Biosciences's Revenue for the three months ended in Jul. 2024 was $0.00 Mil. Therefore, Marvel Biosciences's EBITDA margin for the quarter that ended in Jul. 2024 was 0.00%.


Marvel Biosciences EBITDA Margin % Historical Data

The historical data trend for Marvel Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences EBITDA Margin % Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
EBITDA Margin %
- - - - -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Marvel Biosciences's EBITDA Margin %

For the Biotechnology subindustry, Marvel Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's EBITDA Margin % falls into.



Marvel Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Marvel Biosciences's EBITDA Margin % for the fiscal year that ended in Jul. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2024 )/Revenue (A: Jul. 2024 )
=0/0
= %

Marvel Biosciences's EBITDA Margin % for the quarter that ended in Jul. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jul. 2024 )/Revenue (Q: Jul. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marvel Biosciences  (OTCPK:MBCOF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Marvel Biosciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.